Skip to main content
SpringerLink
Log in

Regional Chemotherapy of Cancer of the Pancreas

  • Chapter
Regional Chemotherapy

Part of the book series: Current Clinical Oncology ((CCO))

  • 101 Accesses

Abstract

Pancreatic cancer (PC) is the fifth most common cause of cancer death among males and females in the United States. In 1999, the American Cancer Society estimated that there would be 29,000 new cases of PC (14,100 men and 14,900 women). Even though 20% of patients elsewhere in the United States may live up to 2 yr, in Louisiana, essentially every patient will die within 2 yr. The longest survival time from the Charity Hospital of Louisiana in New Orleans is only 21 mo (1–3).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Landis SH, Murray T, Bolden S, and Wingo PA. Cancer statistics, 1998, CA Cancer J. Clin., 48 (1998) 6–29.

    Article  PubMed  CAS  Google Scholar 

  2. Janes RH Jr, Niederhuber JE, Chmiel JS, et al. National patterns of care for pancreatic cancer, Ann. Surg., 223 (1996) 261–272.

    Article  PubMed  Google Scholar 

  3. Muchmore JH, Preslan JE, and George WJ. Regional chemotherapy for inoperable pancreatic carcinoma, Cancer, 78 (1996) 664–673.

    PubMed  CAS  Google Scholar 

  4. Krementz ET and Becker ML. Malignant diseases of the pancreas, Adv. Surg., 6 (1972) 205–236.

    PubMed  CAS  Google Scholar 

  5. Fontham ETH and Correa P. Epidemiology of pancreatic cancer, Surg. Clin. N. Am., 69 (1989) 551–567.

    PubMed  CAS  Google Scholar 

  6. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, and Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study, Br. J. Surg., 82 (1995) 111–115.

    Article  PubMed  CAS  Google Scholar 

  7. Chen VW, Xiao-Cheng W, Andrews PA, Correa CN, and Lucas HF. Highlights of cancer incidence in Louisiana, 1988–1992, J. LA. State Med. Soc., 149 (1997) 119–124.

    PubMed  CAS  Google Scholar 

  8. Levin DL and Connelly RR. Cancer of the pancreas. Available epidemiologic information and its implications, Cancer, 31 (1973) 1231–1236.

    Google Scholar 

  9. Gudjonsson B. Cancer of the pancreas: 50 years of surgery, Cancer, 60 (1987) 2284–2303.

    Article  PubMed  CAS  Google Scholar 

  10. Menck HR, Garfinkel L, and Dodd GD. Preliminary report of the National Cancer Data Base, CA., 41 (1991) 7–18.

    PubMed  CAS  Google Scholar 

  11. Brennan MF, Kinsella TJ, and Casper ES. Cancer of the pancreas, In DeVita VT Jr, Hellman S, Rosenberg SA, (eds), Cancer: Principles and Practice of Oncology, 4th ed, Lippincott, Philadelphia, 1993, pp. 849–882.

    Google Scholar 

  12. Evans DB, Abbruzzese JL, and Rich TA. Cancer of the pancreas, In DeVita VT Jr, Hellman S, Rosenberg SA (eds), Cancer: Principles and Practice of Oncology, 5th ed. Lippincott, Philadelphia, 1997, pp. 1054–1087.

    Google Scholar 

  13. Bottger TC, Storkel S, Wellek S, Stockle M, and Junginger T. Factors influencing survival after resection of pancreatic cancer, Cancer, 73 (1994) 63–73.

    Article  PubMed  CAS  Google Scholar 

  14. Nitecki SS, Sarr MG, Colby TV, and van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas, Ann. Surg., 221 (1995) 59–66.

    Article  PubMed  CAS  Google Scholar 

  15. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s. Pathology, complications, and outcomes, Cancer, 226 (1997) 248–260.

    CAS  Google Scholar 

  16. Gall FP and Kockerling F. Problem of radical surgery in pancreatic cancer and its implications for a combined-treatment approach, Rec. Res. Cancer, 110 (1988) 79–86.

    Article  CAS  Google Scholar 

  17. Kobari M, Sunamura M, Ohashi O, Saitoh Y, Yusa T, and Matsuno S. Usefulness of Japanese staging in the prognosis of patients treated operatively for adenocarcinoma of the head of the pancreas, J. Am. Coll. Surg., 182 (1996) 24–32.

    PubMed  CAS  Google Scholar 

  18. Cubilla AL, Fortner J, and Fitzgerald PJ. Lymph node involvement in carcinoma of the head of the pancreas, Cancer, 41 (1978) 880–887.

    Article  PubMed  CAS  Google Scholar 

  19. Nagakawa T, Kobayashi H, Ueno K, Ohta T, Kayahara M, and Miyazaki I Clinical study of the lymphatic flow to paraaortic lymph nodes in carcinoma of the head of the pancreas, Cancer, 73 (1994) 1155–1162.

    Article  PubMed  CAS  Google Scholar 

  20. Nagai H, Kuroda A, and Morioka Y. Lymphatic and local spread of Ti and T2 pancreatic cancer: a study of autopsy material, Ann. Surg., 204 (1986) 65–71.

    Article  PubMed  CAS  Google Scholar 

  21. Tsuchiya R, Oribe T, and Noda T. Size of the tumor and other factors influencing prognosis of carcinoma of the head of the pancreas, Am. J. Gastroenterol., 80 (1985) 459–462.

    PubMed  CAS  Google Scholar 

  22. Nix GAJJ, Dubbelman C, Wilson HP, Schutte HE, Jeekel J, and Postema RR. Prognostic implications of tumor diameter in carcinoma of the head of the pancreas, Cancer, 67 (1991) 529–535.

    Article  PubMed  CAS  Google Scholar 

  23. Warshaw AL. Implications of peritoneal cytology for staging of early pancreatic cancer, Am. J. Surg., 161 (1991) 26–30.

    Article  PubMed  CAS  Google Scholar 

  24. Lei S, Kini J, Kim K, and Howard JM. Pancreatic cancer: cytologic study of peritoneal washings, Arch. Surg., 129 (1994) 639–642.

    Article  PubMed  CAS  Google Scholar 

  25. Leach SD, Rose JA, Lowy AM, et al. Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head, Surgery, 118 (1995) 472–478.

    Article  PubMed  CAS  Google Scholar 

  26. Sperti C, Pasquali C, Piccoli A, and Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas, World J. Surg., 21 (1997) 195–200.

    Article  PubMed  CAS  Google Scholar 

  27. Griffin JF, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma, Cancer, 66 (1990) 56–61.

    Article  PubMed  CAS  Google Scholar 

  28. Allema JH, Reinders ME, van Gulik TM, et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region, Cancer, 75 (1995) 2069–2076.

    Article  PubMed  CAS  Google Scholar 

  29. Willett CG, Lewandrowski K, Warshaw AL, Efird J, and Compton CC. Resection margins in carcinoma of the head of the pancreas, Ann. Surg., 217 (1993) 144–148.

    Article  PubMed  CAS  Google Scholar 

  30. Kalser MH and Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following a curative resection, Arch. Surg., 120 (1985) 899–903.

    Article  PubMed  CAS  Google Scholar 

  31. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following a curative resection of pancreatic cancer, Cancer, 59 (1987) 2006–2010.

    Article  Google Scholar 

  32. Hiraoka T, Watanabe E, Mochinaga M, et al. Intraoperative radiation therapy for patients with pancreatic carcinoma, World J. Surg., 8 (1984) 766–771.

    Article  PubMed  CAS  Google Scholar 

  33. Shipley WU, Tepper JC, Warshaw AL, and Orlow EL. Intraoperative radiation therapy for patients with pancreatic carcinoma, World J. Surg., 8 (1984) 929–934.

    Article  PubMed  CAS  Google Scholar 

  34. Ishikawa O, Hiroaki O, Imaoka S, et al. Is the long-term survival rate improved by preoperative irradiation prior to Whipple’s procedure for adenocarcinoma of the pancreatic head?, Arch. Surg., 129 (1994) 1075–1080.

    Article  PubMed  CAS  Google Scholar 

  35. Warshaw AL and Swanson RS. Pancreatic cancer in 1988. Possibilities and probabilities, Ann. Surg., 208 (1988) 541–553.

    Article  PubMed  CAS  Google Scholar 

  36. Warshaw AL, Gu ZY, Wittenberg J, and Waltman AC. Preoperative staging and assessment of resectability of pancreatic cancer, Arch. Surg., 140 (1990) 230–233.

    Article  Google Scholar 

  37. Foo ML, Gunderson LL, Nagorney DM, et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation ±5 fluorouracil, Int. J. Radiat. Oncol. Biol. Phys., 26 (1993) 483–489.

    Article  PubMed  CAS  Google Scholar 

  38. Staley CA, Lee JE, Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head, Am. J. Surg., 171 (1996) 118–125.

    Article  PubMed  CAS  Google Scholar 

  39. Hoffman JP, Weese JL, Solin LJ, et al. Single institutional experience with preoperative chemoradiotherapy for Stage I-II pancreatic adenocarcinoma, Am. Surg., 59 (1993) 772–781.

    PubMed  CAS  Google Scholar 

  40. Van Heerden JA, McJhath DC, Jlsrup DM, and Weiland LH. Total pancreatectomy for ductal adenocarcinoma of the pancreas: an update, World J. Surg., 12 (1988) 658–662.

    Article  PubMed  Google Scholar 

  41. Martin JK Jr and Goellner JR. Abdominal fluid cytology in patients with gastrointestinal malignant lesions, Mayo Clin. Proc., 61 (1986) 467–471.

    Article  PubMed  Google Scholar 

  42. Jessup JM, Steele G Jr, Mayer RJ, et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma, Arch. Surg., 128 (1993) 559–564.

    Article  PubMed  CAS  Google Scholar 

  43. Trede M, Schwall G, and Salger H. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality, Ann. Surg., 221 (1990) 447–458.

    Article  Google Scholar 

  44. Fernandez-del Castillo C, Rattner DW, and Warshaw AL. Standards for pancreatic resection in 1990s, Arch. Surg., 130 (1995) 295–300.

    Article  PubMed  CAS  Google Scholar 

  45. Ross Hm, Kurtzman SH, Maculy WP, Allen LW, Foster JH, and Deckers PJ. Resection for cure of adenocarcinoma of the head of the pancreas: the greater Hartford experience, Conn. Med., 61 (1997) 3–7.

    Google Scholar 

  46. Geer RJ and Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma, Am. J. Surg., 165 (1993) 68–73.

    Article  PubMed  CAS  Google Scholar 

  47. Conlon KC, Klimstra DS, and Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma: clinicopathologic analysis of 5-year survivors, Ann. Surg., 223 (1996) 273–279.

    Article  PubMed  CAS  Google Scholar 

  48. Satake K, Nishiwaki H, Yokomatsu H, Kawazoe Y, Kim K, and Haku A. Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas, Surg. Gynecol. Obstet., 175 (1992) 259–265.

    PubMed  CAS  Google Scholar 

  49. Fortner JG. Surgical principles for pancreatic cancer: regional total and subtotal pancreatectomy, Cancer, 47 (Suppl 6) (1981) 1712–1718.

    Article  PubMed  CAS  Google Scholar 

  50. Nagakawa T, Kobayashi H, Ueno K, Ohta T, Kayahara M, and Miyazaki I. Clinical study of the lymphatic flow to paraaortic lymph nodes in carcinoma of the head of the pancreas, Cancer, 73 (1994) 1155–1162.

    Article  PubMed  CAS  Google Scholar 

  51. Hirata K, Sato T, Mukaiya M, et al. Results of 1001 pancreatic resections for invasive ductal adenocarcinoma of the pancreas, Arch. Surg., 132 (1997) 771–776.

    Article  PubMed  CAS  Google Scholar 

  52. Mukaiya M, Hirata K, Satoh T, et al. Lack of survival benefit of extended lymph node dissection for ductal adenocarcinoma of the head of the pancreas: retrospective multi-institutional analysis in Japan, World J. Surg., 22 (1998) 248–253.

    Article  PubMed  CAS  Google Scholar 

  53. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, and Miyazaki I. Evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging, Cancer, 72 (1993) 2118–2123.

    Article  PubMed  CAS  Google Scholar 

  54. Beirman HR, Shimkin MB, Byron RL Jr, et al. Effects of intra-arterial administration of nitrogen mustard, Fifth International Cancer Congress, Paris, 1950, p. 186.

    Google Scholar 

  55. Klopp CT, Alford TC, Bateman J, Berry GN, and Winship T. Fractionated intra-arterial cancer chemotherapy with bis-amine hydrochloride: a preliminary report, Ann. Surg., 132 (1950) 811–832.

    Article  PubMed  CAS  Google Scholar 

  56. Schroy PC III, Cohen A, Winawer SJ, and Friedman EA. New chemotherapeutic drug sensitivity assay for colon carcinomas in monolayer culture, Cancer Res., 48 (1988) 3236–3244.

    PubMed  CAS  Google Scholar 

  57. Krementz ET. Regional perfusion. Current sophistication, what next?, Cancer, 57 (1986) 416–432.

    Article  PubMed  CAS  Google Scholar 

  58. Muchmore JH, Carter RD, and Krementz ET. Regional perfusion for malignant melanoma and soft tissue sarcoma: a review, Cancer Invest., 3 (1985) 129–143.

    Article  PubMed  CAS  Google Scholar 

  59. Folkman J. Clinical applications of research on angiogenesis, N. Engl. J. Med., 333 (1995) 1757–1763.

    Article  PubMed  CAS  Google Scholar 

  60. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors, Cancer Met. Rev., 9 (1990) 253–266.

    Article  CAS  Google Scholar 

  61. Ishida H, Makino T, Kobayashi M, and Tsuneoka K. Laparoscopie measurement of pancreatic blood flow, Endoscopy, 15 (1983) 107–110.

    Article  PubMed  CAS  Google Scholar 

  62. Baxter LT and Jain RK. Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics, Microvasc. Res., 40 (1990) 246–263.

    Article  PubMed  CAS  Google Scholar 

  63. Vaupal P. Hypoxia in neoplastic tissue, Microvasc. Res., 13 (1977) 399–408.

    Article  Google Scholar 

  64. Carter SK. Integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma, Cancer Treat. Rev., 3 (1975) 193–214.

    Article  Google Scholar 

  65. Cullinan S, Moertel CG, Wieand HS, et al. Phase III trial on the therapy of advanced pancreatic carcinoma, Cancer, 65 (1990) 2207–2212.

    Article  PubMed  CAS  Google Scholar 

  66. DeCaprio JA, Mayer RJ, Gonin R, and Arbuck SG. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of phase II trial, J. Clin. Oncol., 9 (1991) 2128–2133.

    PubMed  CAS  Google Scholar 

  67. Crooke ST and Bradner WT. Mitomycin C: a review, Cancer Treat. Rep., 3 (1976) 121–139.

    Article  CAS  Google Scholar 

  68. Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, and Wanebo HJ. Rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma, Cancer, 78 (1996) 627–632.

    PubMed  CAS  Google Scholar 

  69. Asbury RF, Cnaan A, Johnson L, Harris J, Zaentz SD, and Haller DG. An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer, Am. J. Clin. Oncol., 17 (1994) 166–169.

    Article  Google Scholar 

  70. Leichman CG, Tangen C, MacDonald JS, Leimert T, and Fleming TR. Phase II trial of amonafide in advanced pancreas cancer: a Southwest Oncology Group trial, Invest. New Drugs, 11 (1993) 219–221.

    Article  PubMed  CAS  Google Scholar 

  71. Bukowski RM, Fleming TR, Macdonald JS, Oishi N, Taylor SA, and Baker LH. Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma: a Southwest Oncology Group study, Cancer, 71 (1993) 322–325.

    Article  PubMed  CAS  Google Scholar 

  72. Moore M, Maroun J, Robert F, et al. Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer, Invest. New Drugs, 11 (1993) 61–65.

    Article  PubMed  CAS  Google Scholar 

  73. Rougier P, De Forni M, Adenis A, et al. Phase II study of Taxotere (RP56976, docetaxel) in pancreatic adenocarcinoma, Proc. Am. Soc. Clin. Oncol., 14 (1995) 221

    Google Scholar 

  74. Moore DF Jr, Pazdur R, Abbruzzese JL, et al. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma, Ann. Oncol., 5 (1994) 286–287.

    PubMed  Google Scholar 

  75. Kilton LJ, Benson AB, Greenberg A, et al. Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas: an Illinois Cancer Center study, Invest. New Drugs, 10 (1992) 201–204.

    Article  PubMed  CAS  Google Scholar 

  76. Casper ES, Green MR, Kelson DP, et al. Phase II trial of gemcitabine (2, 2’-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas, Invest. New Drugs, 12 (1994) 29–34.

    Article  PubMed  CAS  Google Scholar 

  77. Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer, Br. J. Cancer, 73 (1996) 101–105.

    Article  PubMed  CAS  Google Scholar 

  78. Philip PA, Carmichael J, Tonkin K, et al. Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone, Br. J. Cancer, 67 (1993) 379–382.

    Article  PubMed  CAS  Google Scholar 

  79. Hubbard KP, Pazdur R, Ajani JA, et al. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer, Am. J. Clin. Oncol., 15 (1992) 524–527.

    PubMed  CAS  Google Scholar 

  80. Wagener DJ, Verdonk HE, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study, Ann. Oncol., 6 (1995) 129–132.

    PubMed  CAS  Google Scholar 

  81. Kraut EH, Fleming T, MacDonald JS, Spiridonidis CH, Bradof JE, and Baker LH. Phase II trial of merbarone in pancreatic carcinoma: a Southwest Oncology Group study, Am. J. Clin. Oncol., 16 (1993) 327–328.

    Article  PubMed  CAS  Google Scholar 

  82. Friess H, Buchler M, Beglinger C, et al. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer, Pancreas, 8 (1993) 540–545.

    Article  PubMed  CAS  Google Scholar 

  83. Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, and MacDonald JS. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study, J. Clin. Oncol., 15 (1997) 2414–2419.

    PubMed  CAS  Google Scholar 

  84. Jenkins TR, Tangen C, MacDonald JS, Weiss GR, Chapman R, and Hertel A. Phase II trial of piroxantrone in adenocarcinoma of the pancreas: a Southwest Oncology Group study, Invest. New Drugs, 11 (1993) 329–331.

    Article  PubMed  CAS  Google Scholar 

  85. Mahjoubi M, Rougier P, Oliviera J, Herait P, Tigaud JM, and Droz JP. Phase II trial of pirarubicin in the treatment of advanced pancreatic cancer, Cancer Invest., 12 (1994) 403–405.

    Article  PubMed  CAS  Google Scholar 

  86. Scher RM, Kosierowski R, Lusch C, et al. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas, Invest. New Drugs, 13 (1996) 347–354.

    Article  PubMed  CAS  Google Scholar 

  87. Pazdur R, Meropol NJ, Casper ES, et al. Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer, Invest. New Drugs, 13 (1996) 355–358.

    Article  PubMed  CAS  Google Scholar 

  88. Brown TD, Goodman P, Fleming T, MacDonald JS, Hersh EM, and Braun TJ. Phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: a Southwest Oncology Group study, J. Immunother., 10 (1991) 376–378.

    Article  PubMed  CAS  Google Scholar 

  89. Taylor I. Should further studies of chemotherapy be carried out in pancreatic cancer?, Eur. J. Cancer, 29A (Suppl 8) (1993) 1076–1078.

    Article  Google Scholar 

  90. Goldstein Li, Galski H, Fojo A, et al. Expression of multidrug resistance gene in human cancers, J. Nat. Cancer Inst., 81 (1989) 116–124.

    Article  PubMed  CAS  Google Scholar 

  91. Almoquera C, Shibata D, Forrester K, Martin J, Amheim N, and Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, Cell, 53 (1988) 549–554.

    Article  Google Scholar 

  92. Capella G, Cronauer-Mitra S, Peinado MA, and Perucho M. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors, Environ. Health Perspect., 93 (1991) 125–131.

    Article  PubMed  CAS  Google Scholar 

  93. Brentnall TA, Chen R, Lee JG, et al. Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis, Cancer Res., 55 (1995) 4264–4267.

    PubMed  CAS  Google Scholar 

  94. Bos JL. Ras oncogenes in human cancer: a review, Cancer Res., 49 (1989) 4682–4689.

    PubMed  CAS  Google Scholar 

  95. Stokoe D, Macdonald SG, Cadwallader K, Symons M, and Hancock JF. Activation of Raf as a result of recruitment to the plasma membrane, Science, 264 (1994) 1463–1467.

    Article  PubMed  CAS  Google Scholar 

  96. Leevers SJ, Paterson HF, and Marshall O. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane, Nature, 369 (1994) 411–414.

    Article  PubMed  CAS  Google Scholar 

  97. Scarpa A, Capelli P, Mukai K, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations, Am. J. Pathol., 142 (1993) 1534–1543.

    PubMed  CAS  Google Scholar 

  98. Chin K-V, Ueda K, Pastan I, and Gottesman MM. Modulation of the activity of the promoter of the human MDR1 gene by ras and p53, Science, 255 (1992) 459–462.

    Article  PubMed  CAS  Google Scholar 

  99. Miller DW, Fontain M, Kolar C, and Lawson T. Expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines, Cancer Lett., 107 (1996) 301–306.

    Article  PubMed  CAS  Google Scholar 

  100. Verovski VN, Van den Berge DL, Delvaeye MM, Scheper RJ, De Neve WJ, and Storme GA. Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumor PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion, Br. J. Cancer, 73 (1996) 596–602.

    Article  PubMed  CAS  Google Scholar 

  101. Johnston PG, Lentz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors, Cancer Res., 55 (1995) 1407–1412.

    PubMed  CAS  Google Scholar 

  102. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival, J. Clin. Oncol., 14 (1996) 176–182.

    PubMed  CAS  Google Scholar 

  103. Spears CP, Gustaysson BG, Berne M, Frosing R, Bernstein L, and Hayes AA. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil, Cancer Res., 48 (1988) 5894–5900.

    PubMed  CAS  Google Scholar 

  104. Eckman WW, Patlak CS, and Fenstermacher JD. Critical evaluation of principles governing the advantages of intra-arterial infusions, J. Pharmacokinet. Biopharm., 2 (1974) 257–285.

    Article  PubMed  CAS  Google Scholar 

  105. Chen H-SG and Gross JF. Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses, Cancer Treat. Rep., 64 (1980) 31–40.

    PubMed  CAS  Google Scholar 

  106. Collins JM and Dedrick RL. Pharmacokinetics of anticancer drugs, In Chabner B (ed), Pharmacologic Principles of Cancer Treatment, WB Saunders, Philadelphia, 1982, pp. 77–99.

    Google Scholar 

  107. Collins JM. Pharmacokinetics and clinical monitoring, In Chabner BA, Collins JM (eds), Cancer Chemotherapy: Principles and Practice, Lippincott, Philadelphia, 1990, pp. 16–31.

    Google Scholar 

  108. Green RF, Collins JM, Jenkins JF, Speyer JL, and Mycers CE. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols, Cancer Res., 43 (1983) 3417–3421.

    Google Scholar 

  109. Weiss Ai, Metter GE, Fletcher WAS, Wilson WL, Grage TB, and Ramirez G. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity, Cancer Treat. Rep., 60 (1976) 813–822.

    Google Scholar 

  110. Chan KK, Cohen JL, Gross JF, et al. Prediction of adriamycin disposition in cancer patients using physiologic, pharmacokinetic model, Cancer Treat. Rep., 62 (1978) 1161–1171.

    PubMed  CAS  Google Scholar 

  111. Erttmann R, Erb N, Steinhoff A, and Landbeck G. Pharmacokinetics of doxorubicin in man: dose and schedule dependence, J. Cancer Res. Clin. Oncol., 114 (1998) 509–513.

    Article  Google Scholar 

  112. Matsushima Y, Kanazawa F, Hoshi A, et al. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay, Cancer Chemother. Pharmacol., 14 (1985) 104–107.

    Article  PubMed  CAS  Google Scholar 

  113. Mitchell RB, Ratain MJ, and Vogelzang NJ. Experimental rationale for continuous infusion chemotherapy, In Lokich JJ (ed), Cancer Chemotherapy by Infusion, 2nd ed., Precept, Chicago, 1990, pp. 3–34.

    Google Scholar 

  114. Ensminger WD and Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy, Semin. Oncol., 10 (1983) 176–182.

    PubMed  CAS  Google Scholar 

  115. Ensminger WD and Gyves JW. Regional cancer chemotherapy, Cancer Treat. Rep., 68 (1984) 101–115.

    PubMed  CAS  Google Scholar 

  116. Curt GA and Collins JM. Clinical pharmacology of infusional chemotherapy, In Lokich JJ (ed), Cancer Chemotherapy by Infusion, 2nd ed., Precept, Chicago, 1990, pp. 35–41.

    Google Scholar 

  117. Garnick MB, Ensminger WD, and Israel M. Clinical-pharmacological evaluation of hepatic arterial infusion of adriamycin, Cancer Res., 39 (1979) 4105–4110.

    PubMed  CAS  Google Scholar 

  118. Hu E and Howell SB. Pharmacokinetics of intraarterial Mitomycin C in humans, Cancer Res., 43 (1983) 4474–4477.

    PubMed  CAS  Google Scholar 

  119. Ballet F, Vrignaud P, Robert J, Rey C, and Poupon R. Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver, Cancer Chemother. Pharmacol., 19 (1987) 240–245.

    Article  PubMed  CAS  Google Scholar 

  120. Theodors A, Bukowski R, Hewlett J, Livingston R, and Weick J. Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma, Am. J. Clin. Oncol., 5 (1982) 555–558.

    PubMed  CAS  Google Scholar 

  121. Bengmark S and Andren-Sandberg A. Infusion chemotherapy in inoperable pancreatic carcinoma, Rec. Res. Cancer Res., 86 (1983) 13–4.

    Article  CAS  Google Scholar 

  122. Aigner KR, Muller H, and Bessermann R. Intra-arterial chemotherapy with MMC, CDDP and 5-FU for non-resectable pancreatic cancer. A phase II study, Reg. Cancer Treat., 3 (1990) 1–6.

    Google Scholar 

  123. Link KH, Aigner KR, Kuehn W, Schwemmle K, and Kern DH. Prospective correlative chemosensitivity testing in high-dose intra-arterial chemotherapy for liver metastases, Cancer Res.,46 (1986) 4837–4840.

    Google Scholar 

  124. Park J, Kramer BS, Steinberg SM, et al. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based calorimetric assay, Cancer Res., 47 (1987) 5875–5879.

    PubMed  CAS  Google Scholar 

  125. Dedrick RL. Arterial drug infusion: pharmacokinetic problems and pitfalls, JNCI, 80 (1988) 84–89.

    Article  PubMed  CAS  Google Scholar 

  126. Link KH. Basics concepts for the application of mitomycin C in regional cancer treatment, In Taguchi T and Aigner KR (eds), Mitomycin C in Cancer Chemotherapy. Excerpta Medica, Tokyo, 1991, pp. 62–71.

    Google Scholar 

  127. Bold R and McConkey D. Gemcitabine-induced apoptotic cell death of human pancreatic carcinoma is determined by bc1–2 content. 51st Annual Cancer Symposium, Society of Surgical Oncology,1998, p. 57 (Abstract).

    Google Scholar 

  128. Ohigashi H, Ishikawa O, Imaoka S, et al. New method of intra-arterial regional chemotherapy with more selective drug delivery for locally advanced pancreatic cancer, Hepato-Gastroenterology, 43 (1996) 338–345.

    PubMed  CAS  Google Scholar 

  129. Cantore M, Bassi C, Tumulo S, et al. Intra-arterial chemotherapy for Stage III/IV pancreatic cancer. Anti-Cancer Treatment, Sixth International Congress, 1997, p. 133 (Abstract).

    Google Scholar 

  130. Ohigashi H, Ishikawa O, Sasaki Y, et al. Case report of preoperative intra-arterial infusion chemotherapy for pancreatic head carcinoma, Jpn. J. Cancer Chemother., 24 (1997) 1825–1828.

    CAS  Google Scholar 

  131. McCracken JD, Olson M, Cruz AB Jr, Leichman L, and Oishi N. Radiation therapy combined with intra-arterial 5-FU chemotherapy for treatment of localized adenocarcinoma of the pancreas: a Southwest Oncology Group Study, Cancer Treat. Rep., 66 (1982) 549–551.

    PubMed  CAS  Google Scholar 

  132. Wiley AL Jr, Wirtanen GW, Mehta MP, Ramirez G, and Shahabi S. Treatment of probable subclinical liver metastases and gross pancreatic carcinoma with hepatic artery 5-fluorouracil infusion and radiation therapy, Acta. Oncol., 27 (1988) 377–381.

    Article  PubMed  Google Scholar 

  133. Aigner KR and Gailhofer S. Regional chemotherapy for nonresectable, locally metastasized pancreatic cancer: four studies including 164 cases, Reg. Cancer Treat., 1 (Suppl) (1993) A2.

    Google Scholar 

  134. Link KH, Gansauge F, Gorich J, Leder GH, Rilinger N, and Beger HG. Palliative and adjuvant regional chemotherapy in pancreatic cancer, Eur. J. Surg. Oncol., 23 (1997) 409–414.

    Article  PubMed  CAS  Google Scholar 

  135. Ishikawa O, Ohigashi H, Sasaki Y, et al. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas, Am. J. Surg., 168 (1994) 361–364.

    Article  PubMed  CAS  Google Scholar 

  136. Lygidakis NJ and Stringaris K. Adjuvant therapy following pancreatic resection for pancreatic duct carcinoma: a randomized prospective study, Hepato-Gastroenterology, 43 (1996) 671–680.

    PubMed  CAS  Google Scholar 

  137. Dedrick RL, Oldfield EH, and Collins JH. Arterial drug infusion with extracorporeal removal. Theoretical basis with particular reference to the brain, Cancer Treat. Rep., 68 (1984) 373–380.

    PubMed  CAS  Google Scholar 

  138. Oldfield EH, Dedrick RL, Yeager RL, et al. Reduced systemic drug exposure by combining intra-arterial chemotherapy with hemoperfusion of regional venous drainage, J. Neurosurg., 63 (1985) 726–732.

    Article  PubMed  CAS  Google Scholar 

  139. Muchmore JH. Treatment of advanced pancreatic cancer with regional chemotherapy plus hemofiltration, Semin. Surg. Oncol., 11 (1995) 154–167.

    Article  Google Scholar 

  140. Aigner KR, Thiller H, Walther H, and Link KH. Drug filtration in high-dose regional chemotherapy, Contr. Oncol., 29 (1988) 261–280.

    Google Scholar 

  141. Muchmore JH, Krementz ET, Carter RO, Meyer GM, Preslan JE, and George WJ. Management of advanced intra-abdominal malignancy using high-dose intra-arterial chemotherapy with concomitant hemofiltration, Reg. Cancer Treat., 3 (1990) 211–215.

    Google Scholar 

  142. Muchmore JH, Krementz ET, Carter RD, Preslan JE, and George WJ. Treatment of abdominal malignant neoplasms using regional chemotherapy with hemofiltration, Arch. Surg., 126 (1991) 1390–1396.

    Article  PubMed  CAS  Google Scholar 

  143. Aigner KR and Gailhofer S. Celiac axis infusion for locally metastasized pancreatic cancer using spherex/mitoxantron microembolization and mitomycin C/chemofiltration, Reg. Cancer Treat., 4 (1991) 3.

    Google Scholar 

  144. Winchester JF, Rahman A, Tilstone WJ, et al. Sorbent removal of adriamycin in vitro and in vivo, Cancer Treat. Rep., 63 (1979) 1787–1793.

    PubMed  CAS  Google Scholar 

  145. Winchester JF, Rahman A, Tilstone WJ, et al. Will hemoperfusion be useful for cancer chemotherapeutic drug removal?, Clin. Toxicol., 17 (1980) 557–569.

    Article  PubMed  CAS  Google Scholar 

  146. Kihara T, Nakazawa H, Agishi T, Honda H, and Ota K. Superiority of selective bolus infusion and simultaneous rapid removal of anticancer agents by charcoal hemoperfusion in cancer treatment, Trans. Am. Soc. Artif Intern. Organs, 34 (1988) 581–584.

    CAS  Google Scholar 

  147. Ku Y, Saitoh M, Iwaasaki T, et al. Intra-arterial infusion of high-dose adriamycin for unresectable hepatocellular carcinoma using direct hemoperfusion under hepatic venous isolation, Eur. J. Surg. Oncol., (1993) 387–392.

    Google Scholar 

  148. Ku Y, Fukumoto T, Tominaga M, et al. Single catheter technique of hepatic venous isolation and extracorporeal charcoal hemoperfusion for malignant liver tumors, Am. J. Surg., 173 (1997) 103–109.

    Article  PubMed  CAS  Google Scholar 

  149. Ravikumar TS, Pizzorno G, Bodden W, et al. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors, J. Clin. Oncol.,12 (1994) 2723–2736.

    Google Scholar 

  150. Tominaga M, Ku Y, Iwasaki T, Suzuki Y, and Saitoh Y. Pharmacological evaluation of portal venous isolation and charcoal haemoperfusion for high-dose intra-arterial chemotherapy of the pancreas, Br. J. Surg., 84 (1997) 1072–1076.

    Article  PubMed  CAS  Google Scholar 

  151. Myers CE Jr and Chabner BA. Anthracyclines, In Chabner BA, Collins JM (eds), Cancer Chemotherapy, Lippincott, Philadelphia, 1990, pp. 356–381.

    Google Scholar 

  152. Drewinko B, Yang L-Y, Barlogie B, and Trujillo JM. Comparative cytotoxicity of bisantrene, mitoxantrone, ametantrone, dihydroxyanthracenedione, dihydroxyanthracenedione diacetate, and doxorubicin on human cells in vitro, Cancer Res., 43 (1983) 2648–2653.

    PubMed  CAS  Google Scholar 

  153. Fountzilas G, Gratzner H, Lim LO, and Yunis AA. Sensitivity of cultures human pancreatic carcinoma cells to dihyroxyanthracenedione, Int. J. Cancer, 33 (1984) 347–353.

    Article  PubMed  CAS  Google Scholar 

  154. Chan KK, Cohen JL, Gross JF, et al. Prediction of adriamycin disposition in cancer patients using physiologic, pharmacokinetic model, Cancer Treat. Rep., 62 (1978) 1161–1171.

    PubMed  CAS  Google Scholar 

  155. Skibba JL, Jones FE, and Condon RE. Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures, Cancer Treat. Rep., 66 (1982) 1357–1363.

    PubMed  CAS  Google Scholar 

  156. Chaudhuri PK, Arrendondo MA, Crist KA, and Thomford NR. Method of isolated perfusion of pancreas-duodenum in humans, Reg. Cancer Treat., 3 (1990) 7–9.

    Google Scholar 

  157. Crist KA, Arrendondo MA, Chaudhuri B, Thomford NR, and Chaudhuri PK. Pharmacokinetics and toxicity of isolated perfusion of human pancreas-duodenum with mitomycin C, Reg. Cancer Treat., 3 (1991) 305–307.

    Google Scholar 

  158. Tomikawa M, Kubota T, Matsuzaki SW, et al. Mitomycin C and cisplatin increase survival in a human pancreatic cancer metastatic model, Anticancer Res., 17 (1997) 3623–3625.

    PubMed  CAS  Google Scholar 

  159. Yang L, Hwang R, Pandit L, Gordon EM, Anderson WF, and Parekh D. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir, Ann. Surg., 224 (1996) 405–417.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. James H. Muchmore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jyoti Arya
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Cleveland Clinic Taussig Cancer Center, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA

    Maurie Markman MD (Director, Chairman) (Director, Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Muchmore, J.H., Arya, J. (2000). Regional Chemotherapy of Cancer of the Pancreas. In: Markman, M. (eds) Regional Chemotherapy. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-219-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-219-7_7

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9697-0

  • Online ISBN: 978-1-59259-219-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation